OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2023) Vol. 98, Iss. 9, pp. 1465-1487
Open Access | Times Cited: 76
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2023) Vol. 98, Iss. 9, pp. 1465-1487
Open Access | Times Cited: 76
Showing 1-25 of 76 citing articles:
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
Paola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1550-1559
Closed Access | Times Cited: 13
Paola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1550-1559
Closed Access | Times Cited: 13
Improving the management of polycythemia vera patients eligible for cytoreduction: report of a multidisciplinary advisory board
Francesco Ramundo, Elena Rossi, Ketty Peris, et al.
Current Medical Research and Opinion (2025), pp. 1-7
Closed Access | Times Cited: 1
Francesco Ramundo, Elena Rossi, Ketty Peris, et al.
Current Medical Research and Opinion (2025), pp. 1-7
Closed Access | Times Cited: 1
Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification
Jürgen Thiele, H. M. Kvasnicka, Umberto Gianelli, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Jürgen Thiele, H. M. Kvasnicka, Umberto Gianelli, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study
Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, et al.
International Journal of Cancer (2025)
Open Access | Times Cited: 1
Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, et al.
International Journal of Cancer (2025)
Open Access | Times Cited: 1
The triple A model (age, absolute neutrophil count, absolute lymphocyte count‐AAA ) predicts survival and thrombosis in polycythemia vera
Ivan Krečak, Danijela Leković, Isidora Arsenović, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 989-992
Closed Access | Times Cited: 7
Ivan Krečak, Danijela Leković, Isidora Arsenović, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 989-992
Closed Access | Times Cited: 7
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
Ayalew Tefferi, Animesh Pardanani
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Ayalew Tefferi, Animesh Pardanani
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Tris(2-chloroethyl) Phosphate Leads to Unbalanced Circulating Erythrocyte in Mice by Activating both Medullary and Extramedullary Erythropoiesis
Jingxu Zhang, Chun‐Feng Liu, Jian Ding, et al.
Environmental Science & Technology (2025)
Closed Access
Jingxu Zhang, Chun‐Feng Liu, Jian Ding, et al.
Environmental Science & Technology (2025)
Closed Access
Reversibility of acrocyanosis and improvement of capillaroscopic pattern in a patient with polycythemia vera treated with ruxolitinib: a case report
Angelo Nigro
Blood Research (2025) Vol. 60, Iss. 1
Open Access
Angelo Nigro
Blood Research (2025) Vol. 60, Iss. 1
Open Access
Multiple‐Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects
Nishit B. Modi, Phillip Dinh, Ifode Ajari
Clinical Pharmacology in Drug Development (2025)
Open Access
Nishit B. Modi, Phillip Dinh, Ifode Ajari
Clinical Pharmacology in Drug Development (2025)
Open Access
Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system
E. Walter, Francesca Torelli, Tiziano Barbui
Annals of Hematology (2025)
Open Access
E. Walter, Francesca Torelli, Tiziano Barbui
Annals of Hematology (2025)
Open Access
Response to Comment on “Features and Allele Frequency of JAK2 Exon 12-mutated Polycythemia Vera and a Comparison With JAK2V617F-mutated Disease”
Chiao‐Hsiung Chuang, Ming‐Chung Kuo, Lee‐Yung Shih
Archives of Medical Research (2025) Vol. 56, Iss. 4, pp. 103178-103178
Closed Access
Chiao‐Hsiung Chuang, Ming‐Chung Kuo, Lee‐Yung Shih
Archives of Medical Research (2025) Vol. 56, Iss. 4, pp. 103178-103178
Closed Access
Hemoglobin levels for the diagnosis of polycythemia Vera: How high is high enough?
Uğur Koca, Enes Seyda Şahiner, Özge Soyer Kösemehmetoğlu, et al.
European Journal of Internal Medicine (2025)
Closed Access
Uğur Koca, Enes Seyda Şahiner, Özge Soyer Kösemehmetoğlu, et al.
European Journal of Internal Medicine (2025)
Closed Access
Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM)
Ivan Krečak, Marko Lucijanić, Rajko Kušec
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1524-1524
Open Access
Ivan Krečak, Marko Lucijanić, Rajko Kušec
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1524-1524
Open Access
Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management
Tiziano Barbui, Valerio De Stefano, Elena Rossi, et al.
American Journal of Hematology (2025)
Closed Access
Tiziano Barbui, Valerio De Stefano, Elena Rossi, et al.
American Journal of Hematology (2025)
Closed Access
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera
Yan Beauverd, Jean‐Christophe Ianotto, Kyaw Htin Thaw, et al.
Leukemia (2025)
Open Access
Yan Beauverd, Jean‐Christophe Ianotto, Kyaw Htin Thaw, et al.
Leukemia (2025)
Open Access
Contemporary Topics in Myeloproliferative Neoplasms and Myelodysplastic Syndromes: American Journal of Hematology 100th Volume Anniversary Symposium
Carlo Brugnara, Alessandro M. Vannucchi, Ayalew Tefferi
American Journal of Hematology (2025)
Closed Access
Carlo Brugnara, Alessandro M. Vannucchi, Ayalew Tefferi
American Journal of Hematology (2025)
Closed Access
Immunosuppression of spleen in mice treated with erythropoietin: transcriptomic and immunological analysis
Xuanxin Lyu, Jiahao Shi, Qi Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Xuanxin Lyu, Jiahao Shi, Qi Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Myocardial Infarction in Polycythemia Vera and Dengue: A Case of Competing Risks
Maria Politi, Guido Vannoni, Juan Gagliardi
Cureus (2025)
Open Access
Maria Politi, Guido Vannoni, Juan Gagliardi
Cureus (2025)
Open Access
Impact of ELN clinical signs and symptoms on the thrombotic risk in Polycythemia Vera patients treated with front-line hydroxyurea
Francesca Palandri, Massimo Breccia, Elena Maria Elli, et al.
Research Square (Research Square) (2025)
Closed Access
Francesca Palandri, Massimo Breccia, Elena Maria Elli, et al.
Research Square (Research Square) (2025)
Closed Access
Clinical features and outcomes of JAK2 unmutated erythrocytosis
Jeong Suk Koh, Wonhyoung Seo, Sora Kang, et al.
Blood Research (2025) Vol. 60, Iss. 1
Open Access
Jeong Suk Koh, Wonhyoung Seo, Sora Kang, et al.
Blood Research (2025) Vol. 60, Iss. 1
Open Access
Exploring perceptions in the management and treatment of polycythaemia vera in the UK
Becky Bagnall, Claire Woodley, Rozinder Bains, et al.
Annals of Hematology (2025)
Open Access
Becky Bagnall, Claire Woodley, Rozinder Bains, et al.
Annals of Hematology (2025)
Open Access
Impact of Ruxolitinib Interactions on JAK2 JH1 Domain Dynamics
Hong Nhung Vu, Ragousandirane Radjasandirane, Julien Diharce, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3727-3727
Open Access
Hong Nhung Vu, Ragousandirane Radjasandirane, Julien Diharce, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3727-3727
Open Access
Polycythaemia vera
Claire Harrison, Tiziano Barbui, Prithviraj Bose, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access
Claire Harrison, Tiziano Barbui, Prithviraj Bose, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access
Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis
Olga Morath, Jenny Rinke, Andrew J. Walter, et al.
Annals of Hematology (2025)
Open Access
Olga Morath, Jenny Rinke, Andrew J. Walter, et al.
Annals of Hematology (2025)
Open Access
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
Tiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
Annals of Hematology (2023) Vol. 103, Iss. 2, pp. 437-442
Closed Access | Times Cited: 10
Tiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
Annals of Hematology (2023) Vol. 103, Iss. 2, pp. 437-442
Closed Access | Times Cited: 10
